Compare CION & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CION | INBX |
|---|---|---|
| Founded | 2011 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 527.0M | 430.2M |
| IPO Year | N/A | 2020 |
| Metric | CION | INBX |
|---|---|---|
| Price | $9.55 | $80.11 |
| Analyst Decision | Sell | Hold |
| Analyst Count | 1 | 2 |
| Target Price | ★ $8.50 | N/A |
| AVG Volume (30 Days) | ★ 413.5K | 242.1K |
| Earning Date | 11-06-2025 | 11-14-2025 |
| Dividend Yield | ★ 15.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.49 | N/A |
| Revenue | ★ $244,923,000.00 | $1,400,000.00 |
| Revenue This Year | N/A | $563.00 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $19.50 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.51 | $10.81 |
| 52 Week High | $12.71 | $94.57 |
| Indicator | CION | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 41.17 | 49.85 |
| Support Level | $9.43 | $76.22 |
| Resistance Level | $10.17 | $94.57 |
| Average True Range (ATR) | 0.19 | 7.21 |
| MACD | -0.07 | -1.31 |
| Stochastic Oscillator | 11.86 | 28.54 |
CION Invt Corp is an externally managed, non-diversified, closed-end management investment company that has elected to be regulated as a business development company. The Company's portfolio is comprised of investments in senior secured debt, including first lien loans, second lien loans, and unitranche loans, and, to a lesser extent, collateralized securities, structured products and other similar securities, unsecured debt, and equity, of private and thinly-traded U.S. middle-market companies. Its investment objective is to generate current income and, to a lesser extent, capital appreciation for investors.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.